Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 21;13:1221352. doi: 10.3389/fonc.2023.1221352

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Tanaka, Enokida, Okano, Fujisawa, Tanaka, Takeshita, Onaga, Hoshi, Wada, Sato, Ueda and Tahara

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Prognosis of patients treated with PE-based chemotherapy following ICI monotherapy. A, B: Progression-free survival (A) and overall survival (B) from the initiation of PE-based chemotherapy in all patients. (C, D) Progression-free survival 2 (PFS 2) (C) and overall survival (OSici) (D) from initiation of immune checkpoint inhibitors in all patients. PCE, paclitaxel+carboplatin+cetuximab; PTX+Cmab, paclitaxel+cetuximab; PFS, progression-free survival; OS, overall survival; PFS2, progression-free survival 2; CI, confidence interval; ICI, immune checkpoint inhibitor. Note: PE-based chemotherapy, PCE or PTX+Cmab; ICI, pembrolizumab or nivolumab; OSici, overall survival from initiation of immune checkpoint inhibitors.